YPL-001

YPL-001 is an investigational, orally administered standardized botanical drug candidate developed by Yungjin Pharm for chronic obstructive pulmonary disease. It is a defined extract from the aerial parts of *Pseudolysimachion rotundum* subsp. *subintegrum* containing six iridoid glycosides: piscroside C, verproside, isovanillyl catalpol, picroside II, 6-O-veratroyl catalpol, and catalposide. In cellular and cigarette-smoke-exposure animal models, YPL-001 reduced inflammatory signaling and apoptosis while enhancing antioxidant responses, including increased HDAC2 activity, suppression of NF-kappa-B activity, and activation of the Nrf2 pathway. A randomized, placebo-controlled Phase 2a study in moderate-to-severe COPD evaluated oral 80 mg and 160 mg twice-daily regimens and is listed as completed. ([drugs.ncats.io](https://drugs.ncats.io/drug/f922faa7))

Other names

YPL 001YPL001YPL-001Pseudolysimachion rotundum subsp. subintegrum aerial parts extract